Mallory Cowart

Peds ID and Antimicrobial Stewardship PharmD; pediatric patient advocate

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

Myth:Bactrim is not active against β-hemolytic Streptococcus,is now totally BUSTED
🆕️🔥 @ChristianCho
In vitro activity against clinical isolates of β-hemolytic Strept via BMD
TMP/SMX:100%🌟
Clinda:85%
Doxy:57%
For S.pyogenes TMP/SMX was 100% S #idxposts
https://t.co/5uhHS72mZm

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

This one is 🔥 by our @SIDPharm
🌟 @katie_b_olney @bill_olney
@JHospMedicine
Things We Do for No Reason™: Prescribe cefdinir for treatment of common infections #downwithcefdinir #IDXposts
https://t.co/tMPz0TMrxl

[SIDP @SIDPharm]

Any #Swifties out there? Antibiotic Eras dropping hot today. #StewardsVersion

[Tiffany LaDow, PharmD @LadowTiffany]

If someone told me abx stewardship would be giving unsolicited advice and navigating pushback - I would’ve picked another job

But it’s more good communication and emotional intelligence than anything else

Clear is kind 🤝 active listening
Accepted recs & 🫶🏻 Pt care

[Cure CMD @CureCMD]

Happy #RareDiseaseDay from all of us here at Cure CMD! 🧡💙

[Mallory Cowart @PedPharmASP]

@julie_justo @MaxJordan_N @PaulSaxMD @acog @CIDJournal Hoping to share more data soon from our group - we switched to ceftriaxone/metronidazole!

[Guillermo Rodriguez-Nava (Guiro) @G_ROD_11]

Ceftriaxone is actually abbreviated CRO, not CTX.

[SIDP @SIDPharm]

We’re ID Pharmacists, of course we’re going to ask you about those antibiotic allergies 💊 #WeareID

[Brad Spellberg @BradSpellberg]

Updated Shorter Is Better tables with 3 changes! Included 2 peds UTI studies, thanks to @absteward & @AlbertoEMaraolo for finding. Included cystic fibrosis exacerbation, thanks to @pulmcrit for finding. References with commentary at https://t.co/1oaAT6Cybb

[ORMC Pharmacy Residency @ORMCPharmRes]

✔️Mark your calendars! 🗓️
We are excited to announce the dates for our upcoming virtual info sessions! Sign up via the link in our bio. We hope to see you there 🎉

[Mallory Cowart @PedPharmASP]

@sadiegiuliani We did at Orlando Health!

[Pediatric Pharmacy Association | PPA @PediatRxAssn]

Be sure to catch When Life Gives You Antibiotic Shortages, Make Antibiotic Stewardship at the #PPA23Conf!

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕️⚡️🔥Retrospective, multicenter, observational cohort
High-dose oral beta-lactams were as safe and effective as oral FQ or TMP/SMX for the treatment of bacteremia from a urinary source. Most patients received 8–10 days of therapy in both groups
https://t.co/bBaunoUJZV

[Mallory Cowart @PedPharmASP]

@helennewland That is our current plan but working on getting it added to formulary and waiting for it to become available so it’s possible that plan could change.

[Mallory Cowart @PedPharmASP]

🥳🥳

[Chelsea Cooley, PharmD, BCPPS @peds_pharmD]

Officially the new PGY2 pediatric RPD for Akron Children’s! So excited to recruit for next year 🥳 #TwitteRx

[Allison Chung, Pharm.D, BCPPS, FCCP, FPPA(She/Her) @lilhwn2]

Anyone caring for kids or who will come across meds 4 kids.. retail pharmacists included! This is great resource, KIDS List..my student summarizes article in an infographic! Reference for article is on infogaphic! Please circulate!! #PedsICU #PedsPharm #KIDS #PedsRx #PedsRxUs

[Pharmacotherapy @PharmacoJournal]

PK/PD properties, clinical efficacy & safety data, dosing considerations & subsequent role in therapy for ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, ceftolozane-tazobactam, & cefiderocol in pediatric pts. FREE TO READ https://t.co/DywFDCoJfT

[Mallory Cowart @PedPharmASP]

@peds_pharmD 🥰😍

[Mallory Cowart @PedPharmASP]

@PaulSaxMD We mostly use it for MDR NTM in our cystic fibrosis patients. Overall works well in our experience and most patients tolerate it without many adverse effects. We often have to titrate up dosing due to low levels.

[Mallory Cowart @PedPharmASP]

@Billicillin We do clindamycin and unless persistent positive bacteremia typically only 48-72 hours of IV therapy before switching to PO as long as CRP downtrending